Clinical Research

LMC has received approval from the National Committee for Clinical Research (NCCR), to set up its own Independent Ethics Committee (IEC), in April 2019, with Dr Lucas Luk Tien Wee as our inaugural Chairperson. LMC looks forward to be actively involved in clinical trials, to further develop healthcare technology and enhance healthcare provision to our community.

To date, we have 2 clinical trials registered with the National Medical Research Registry (NMRR), with Dr Lucas Luk Tien Wee as Primary Investigator for both proposed studies:

1. REGEN Trial -Human Mesenchymal Stem Cell (hMSC) Infusion for Anti-Aging and REGENerative Therapy, A Phase 1 Investigator Initiated Clinical Trial (NMRR-19-2462-50562 ) – Pending NSCERT Approval

The REGEN Trial is a study on the effects of human mesenchymal stem cell (hMSC) infusion on humans, with regards to anti-aging and regenerative therapy. The study will look at 100 healthy subjects and aim to assess both patient safety, as well as, if any tangible health benefits can be demonstrated from the infusion of hMSCs in our human subjects.

For more information, please contact our centre, to speak to our doctor in charge.

(Please view our Patient Information Section (coming soon), for public education materials on general health advice and information, including educational articles regarding Stem Cells.)

2. N2D CAR γδT Trial for Solid Tumours – A Phase I Dose-escalation Trial to Evaluate Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D) in Subjects with Relapsed or Refractory Solid Tumour ( NMRR-19-2594-50743 ) – Pending NSCERT Approval

The N2D CAR γδT Trial for Solid Tumours involves 9 subjects with advanced solid tumours, that have been deemed to be refractory to conventional cancer treatment. The study aims to discern the safety and efficacy of CytoMed Therapeutic’s (Malaysia) patented novel N2D CAR γδT (CTM-N2D) therapy in human subjects.

CAR-T Therapy is considered the next frontier of cancer management and has shown much potential in the management of advanced blood cancers, in both laboratory and clinical trials. However, the cost of available CAR-T therapy is at present extremely hefty, easily >RM1 Million for the duration of treatment. LMC is collaborating with a locally based biotechnology company to locally produce and administer the treatment of this novel CAR-T Therapy, in not only blood, but solid cancers. We envision to provide this new-age CAR-T Therapy for our local populace, at a much more affordable cost.

For more information, please contact our centre, to speak to our doctor in charge.

(Please view our Patient Information Section (coming soon), for public education materials on general health advice and information, including educational articles regarding Recent Advances in Cancer Therapy.)